| Literature DB >> 14562858 |
Abstract
The non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) has been used as a component of salvage therapy for patients who have experienced virologic failure while taking nucleosides and protease inhibitors (PIs). In spite of broad cross-resistance within the NNRTI class, NVP may also play a role in salvage therapy for patients who have experienced failure while taking NNRTIs Another role for NVP in treatment-experienced patients is in so-called "PI switch" strategies, in which NVP is substituted for a PI within a virologically successful combination regimen. This paper reviews the clinical data that support the use of NVP in salvage regimens and PI switch strategies.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14562858 DOI: 10.1097/00126334-200309011-00008
Source DB: PubMed Journal: J Acquir Immune Defic Syndr ISSN: 1525-4135 Impact factor: 3.731